PixarBio Corp. To Establish Medical Research Center-Corporate Headquarters In Medford, Massachusetts
12/13/2013
Located in close proximity to its innovation roots at Harvard and MIT, PixarBio Corp. said it will have capacity to quickly expand beyond biomaterials needed for Parkinson’s disease to include biomaterials for Epilepsy.
“We are building a home for our world renowned and award winning team of researchers to drive innovation and accelerate the development of new treatment options for Parkinson’s disease. We’re confident that our optimized R&D model will generate key intellectual property permitting PixarBio to lead the development of next generation biomaterials for the treatment of Parkinson’s disease as well as a range of chronic neurological conditions,” says CTO Randy Holmes-Farley, PhD.
Frank Reynolds, PixarBio’s CEO adds, “We’ll move to Medford, MA in early 2014 and get to work on achieving our objective of rapidly bringing a new Parkinson’s treatment to market. Along the way we’ll explore M&A in the biomaterials space while focusing on expanding our platform.”
Project Announcements
NSP Panels Establishes Mullins, South Carolina, Manufacturing Operations
03/25/2026
United Composite Materials Plans Greenville County, South Carolina, Manufacturing Operations
03/25/2026
Van-Am Expands St. Joseph, Missouri, Operations
03/25/2026
Lufburrow & Company Plans Aberdeen, Maryland, Manufacturing Operations
03/24/2026
Autokiniton Expands Bellevue, Ohio, Manufacturing Operations
03/24/2026
Philip Morris International Plans Tampa, Florida, Operations
03/24/2026
Most Read
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024
-
Economic Developer Role Shifting from Deal-Making to Systems Stewardship
Q1 2026
-
What Companies Need from Modern Manufacturing Sites
Q1 2026
-
Capitalizing on the OBBBA Before the 2026 Cliff
Q1 2026
-
Last Word: Don’t Lose by Winning
Q1 2026
-
Advanced Manufacturing Isn’t a Buzzword—It’s a Different Location Strategy
Q1 2026
-
The Geography of Packaging: Why Location Strategy Matters More Than Ever
Q1 2026